Csl

New biotech incubator welcomes expressions of interest

28-Nov-2022 By Rachel Arthur

A new biotech incubator, which will be located at CSL’s new Global Headquarters in Melbourne, Australia, is welcoming expressions of interest ahead of its 2024 launch.

FDA approves first gene therapy for hemophilia B

24-Nov-2022 By Rachel Arthur

CSL’s Hemgenix (etranacogene dezaparvovec-drlb) becomes the first treatment to offer patients freedom from regular ongoing infusions.

CSL inaugurates new R&D center in Germany

15-Sep-2022 By Rachel Arthur

The €150m ($150m) new facility will become CSL’s largest R&D site: with more than 500 employees and a multitude of disciplines.

‘A critical and very exciting milestone’: Approval of domestically manufactured COVID-19 vaccine boosts Australia’s vaccination campaign

22-Mar-2021 By Rachel Arthur

Australia’s Therapeutic Goods Administration (TGA) has approved manufacture of the AstraZeneca COVID-19 vaccine by CSL – Seqirus: reducing the country's dependence on limited supply from abroad and allowing a wider vaccination campaign to begin....

Australia announces deal for 84 million COVID-19 vaccine doses

07-Sep-2020 By Rachel Arthur

The Australian Government has made a $1.7bn AUD ($1.24bn USD) supply and production agreement for COVID-19 vaccines: with the first doses set to come from AstraZeneca’s vaccine in January 2021.